Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Keyword(s):
Keyword(s):
Keyword(s):